Cargando…

The Association Between HbA(1c) and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)

OBJECTIVE: According to recent guidelines, individuals with type 1 diabetes should spend <4.0% of time per day with glucose levels <3.9 mmol/L (<70 mg/dL) and <1.0% per day with glucose levels <3.0 mmol/L (<54 mg/dL). RESEARCH DESIGN AND METHODS: In the GOLD randomized crossover tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyed Ahmadi, Shilan, Westman, Klara, Pivodic, Aldina, Ólafsdóttir, Arndís F., Dahlqvist, Sofia, Hirsch, Irl B., Hellman, Jarl, Ekelund, Magnus, Heise, Tim, Polonsky, William, Wijkman, Magnus, Schwarcz, Erik, Lind, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440892/
https://www.ncbi.nlm.nih.gov/pubmed/32641374
http://dx.doi.org/10.2337/dc19-2606
Descripción
Sumario:OBJECTIVE: According to recent guidelines, individuals with type 1 diabetes should spend <4.0% of time per day with glucose levels <3.9 mmol/L (<70 mg/dL) and <1.0% per day with glucose levels <3.0 mmol/L (<54 mg/dL). RESEARCH DESIGN AND METHODS: In the GOLD randomized crossover trial, 161 individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) were randomized to continuous glucose monitoring (CGM) or conventional therapy with self-monitoring of blood glucose (SMBG) and evaluated over 16 months. We estimated the association between time spent in hypoglycemia and various mean glucose and HbA(1c) levels. RESULTS: Time spent in hypoglycemia (<3.9 mmol/L and <3.0 mmol/L) increased significantly with lower mean HbA(1c) and mean glucose levels during both CGM and conventional therapy. During CGM, 24 (57.1%) individuals with HbA(1c) <7.5% (<58 mmol/mol) had <1.0% time spent in hypoglycemia <3.0 mmol/L and 23 (54.8%) had <4.0% time spent in hypoglycemia <3.9 mmol/L. During CGM, mean time spent in hypoglycemia for individuals with mean HbA(1c) 7.0% (52 mmol/mol) was estimated to be 5.4% for <3.9 mmol/L and 1.5% for <3.0 mmol/L. The corresponding values during SMBG were 9.2% and 3.5%, respectively. Individuals with mean glucose levels of 8 mmol/L spent 4.9% units more time with glucose levels <3.9 mmol/L and 2.8% units more time <3.0 mmol/L during SMBG compared with CGM. CONCLUSIONS: Reaching current targets for time in hypoglycemia while at the same time reaching HbA(1c) targets is challenging for patients with type 1 diabetes treated with MDI both with CGM and SMBG monitoring. However, CGM is associated with considerably less time in hypoglycemia than SMBG at a broad range of HbA(1c) levels and is crucial for patients with MDI treatment if they are to have a chance to approach hypoglycemia targets.